Form 4: Akero Therapeutics Executive Granted Stock Options

Scott A. Gangloff, Chief Technology Officer of Akero Therapeutics, received stock options for 225,000 shares on April 29, 2024.

Summary

• Scott A. Gangloff, the Chief Technology Officer of Akero Therapeutics, Inc. (AKRO), was granted stock options to purchase 225,000 shares of common stock on April 29, 2024.
• The exercise price of the options is $19.62 per share.
• The options vest over time, with 25% vesting on April 29, 2025, and the remaining 75% vesting in 36 equal monthly installments thereafter, contingent upon continued service.
• The options expire on April 28, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Madrigal Pharmaceuticals and Viking Therapeutics also utilize stock options to incentivize their leadership teams.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term commitment and performance.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CTO to drive company performance.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates